Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SeaStar Medical Holding (ICU) Gains from Sales and Divestitures (2023 - 2025)

Historic Gains from Sales and Divestitures for SeaStar Medical Holding (ICU) over the last 3 years, with Q3 2025 value amounting to $76384.0.

  • SeaStar Medical Holding's Gains from Sales and Divestitures rose 73179.79% to $76384.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $76384.0, marking a year-over-year increase of 73179.79%. This contributed to the annual value of $9183.0 for FY2024, which is 9554.11% down from last year.
  • As of Q3 2025, SeaStar Medical Holding's Gains from Sales and Divestitures stood at $76384.0, which was up 73179.79% from $13295.0 recorded in Q2 2025.
  • SeaStar Medical Holding's 5-year Gains from Sales and Divestitures high stood at $364844.0 for Q3 2023, and its period low was $7417.0 during Q1 2025.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $16492.0 (2024), whereas its average is $86854.1.
  • Per our database at Business Quant, SeaStar Medical Holding's Gains from Sales and Divestitures tumbled by 9748.3% in 2024 and then soared by 73179.79% in 2025.
  • SeaStar Medical Holding's Gains from Sales and Divestitures (Quarter) stood at $205947.0 in 2023, then plummeted by 95.54% to $9183.0 in 2024, then surged by 731.8% to $76384.0 in 2025.
  • Its last three reported values are $76384.0 in Q3 2025, $13295.0 for Q2 2025, and $7417.0 during Q1 2025.